[null, null, {"document_url": "http://sdbj.com/news/2017/oct/26/diet-pill-maker-orexigen-losing-race-profits/", "unformatted_src": "https://ocbj.media.clients.ellingtoncms.com/img/photos/2017/10/25/Orexigen-10-30-17-web.jpg", "src": "https://ocbj.media.clients.ellingtoncms.com/img/photos/2017/10/25/Orexigen-10-30-17-web.jpg", "formatted_filename": "Orexigen web", "alt_text": "photo"}, null, {"document_url": "http://sdbj.com/news/2017/oct/26/diet-pill-maker-orexigen-losing-race-profits/", "unformatted_src": "//i.imgur.com/MISvQTv.png", "src": "http://i.imgur.com/MISvQTv.png", "formatted_filename": "MISvQTv", "rendered_width": 240}, null]
Michael Narachi, CEO for Orexigen. Photo by Jamie Scott Lytle. San Diego  Diet pill maker Orexigen Therapeutics, one of San Diego’s struggling public companies, may soon auction itself off to the highest bidder in an attempt to fortify its finances...
 Yours for only $129
